Alex Yang, J.D., LL.M. is the CEO/owner of Mstone Partners,
which serves as the major shareholder of Polaryx. Since 2016,
Alex has served in senior management and chair of board roles
for a number of biopharmaceutical companies. Prior to the
biotech incubation platform, Alex has over 25 years of
experience in advising and executing fund formation,
cross-border transactions, and a diverse pool of investment
experiences in multiple industry sectors. He currently serves
investment and risk committee member roles for various
regional and country-focused private equity funds. Alex was
formerly a managing partner at Kim & Chang and a partner at
the Ernst & Young Hong Kong office leading regional financial
services practice, including banking and capital markets,
asset management, and insurance.
Alex formerly worked at the Morgan Stanley Hong Kong Office in
the capacity of its Asia Private Equity and In-house Counsel,
focused on buy-outs and grow-capital investments, real estate,
special situation, and infrastructure transactions across
Asia. He also worked at Coopers & Lybrand and Ernst & Young
New York offices in their international tax and consulting
divisions.
Alex graduated from New York University School of Law with
both Juris Doctor (J.D.) and Master of Laws (LL.M.) degrees
and a bar with the State of New York and received an
undergraduate degree from Binghamton University in Economics.
Ronald Moss, M.D., is a board-certified allergist/immunologist
and has over 30 years of experience leading the clinical
development of high-value pipelines that resulted in
regulatory approvals and strategic alliances. Prior to joining
Polaryx, Ron was most recently the Chief Executive Officer at
Red Queen Therapeutics where he led clinical and preclinical
research, business development, corporate strategy, and
intellectual property management. He has held various
executive roles of increasing responsibilities at Adamis
Pharmaceuticals, Ansun Biopharma, Nexbio, Telos
Pharmaceuticals, and Merck & Co., and oversaw clinical
programs across multiple therapeutic areas. In addition to his
executive roles, Ron also serves as a Director on the Board of
Biosortia Pharmaceuticals.
Ron holds a Doctor of Medicine (M.D.) degree from the Chicago
Medical School and completed his residency in pediatrics at
the State University of New York at Stony Brooks. He also
completed his extensive post-doctoral fellowship training in
Allergy and Immunology at the National Institute of Health.
Rama is a highly accomplished senior scientific professional and visionary leader with over 20 years of achievements in pharmaceutical development, regulatory approvals, and commercial manufacturing.
Rama has a demonstrated record in leading strategic, operational, scientific and regulatory aspects of CMC development, manufacturing and supply chain across all stages: discovery, preclinical, clinical, regulatory approval, launch and commercialization. She has advanced 25+ new chemical entities on a speed to market timeline, with strong emphasis on science, innovation, and quality in various therapeutic areas, including Oncology, Autoimmune Diseases, Immunology and inflammation, Pain, Renal, Virology and Neuroscience.
Rama holds a Bachelor of Science degree in Pharmacy from the College of Pharmacy, University of Jordan - Amman, Jordan, and a Ph.D. in Pharmaceutics at the College of Pharmacy, University of Iowa - Iowa City, IA.
Rama has also received the Upjohn-Enz Commitment for Excellence Award by Pharmacia, and the Pharmacy Graduate Program Excellence Award.
Luis A Rojas M.Sc., Ph.D. is Polaryx’s Chief Clinical
Development Officer. Luis is a highly experienced Research
Scientist Statistician with 30+ years in the pharmaceutical,
medical device, CRO, and academia industries. Luis is a
Subject-Matter Expert in Study Design / Adaptive Design for
Phase I through Phase IV studies and has amassed more than 20
years of leadership and project management experience,
including managing global staff of 140+ Biostatisticians and
Statistical Programmers.
Luis was the former Head of Study Designs / Adaptive Design
unit within Advisory Service Analytics / Center for Statistics
in Drug Development in IQVIA, while acting as lead Senior
Research Scientist Statistician for the GI, Rare Diseases,
Ophthalmology, CNS, Lupus, RA Center of Excellence. Luis
received his Ph.D. in Research Statistics from Rafael Belloso
Chacin, Venezuela.
Hahn-Jun Lee, M.Sc., Ph.D. is a serial entrepreneur who
founded or co-founded Polaryx, Epygenix Therapeutics and Focus
Therapeutics, a business catalyst in the biotech-pharma
industry. He also co-founded Curyx Partners, LLC, a drug
development platform. Hahn-Jun has extensive experience in
R&D, deal making, business development, and has consulted with
several top-notch health care venture capital firms and global
pharma and biotech companies, including Doman Associates,
Shire Human Genetic Therapies, P&G Pharma, Melior Discovery,
and CDI. He also consulted with several Korean biotechs,
venture capital firms, and research institutes.
Hahn-Jun was an Assistant Professor of Biotechnology in the
Department of Orthopedic Surgery, College of Physicians and
Surgeons, Columbia University in the City of New York. He also
worked as a Staff Scientist at the RIKEN Brain Science
Institute in Japan. He obtained a B.Sc. in Life Science from
Sogang University, Seoul, Korea and completed his M.Sc. and
Ph.D. in applied biotechnology in the Department of Applied
Biotechnology at the University of Tokyo, Japan.
G. Michael Landis, C.P.A., is a highly accomplished financial
executive who brings an over 25-year track record of public
company expertise, capital market transactions, investor
relations, and financial report. Immediately prior to joining
Polaryx, Mike was Chief Financial Officer at Epygenix
Therapeutics, a late-stage clinical biopharmaceutical company
that was recently acquired in April 2024. Mike was also the
Chief Financial Officer at Avisa Diagnostics Inc., a publicly
traded medical device company. While there, he was responsible
for strategic and tactical finance initiatives and was
directly involved with investor relations and capital-raising
activities. He also served as Principal Accounting Officer and
Treasurer at Lannett Company Inc., a publicly traded
pharmaceutical company, where he led acquisitions and related
financing activities, and was a member of the executive team
that successfully completed a $1.2 billion acquisition. Mike
was actively involved in the Initial Public Offering (IPO)
process in previous financial leadership roles at companies
including Akrion Inc. and AlliedBarton Security Services, LLC.
Mike has also worked at various other publicly traded
companies after beginning his career within the Big Four
public accounting firms.
Mike holds a Bachelor of Arts degree in accounting from
Franklin & Marshall College in Lancaster, PA and is a
Certified Public Accountant (C.P.A.)
Andrew O has over twenty years of experience as an asset
management and finance professional. Prior to serving as
Polaryx’s Chief Investment Officer, Andrew held multiple
positions within traditional fund management as well
fundamentally-driven hedge fund investing roles at
institutions such as Manulife Investment Management, Horizon
Asset International, and FrontPoint Partners (Morgan Stanley).
Andrew also worked at Goldman Sachs and the International
Finance Corporation, the World Bank’s private investment arm.
Andrew graduated from the University of Pennsylvania and
undertook Master’s level studies at Yonsei University’s
Graduate School of International Studies.
Jay Vijayan, Ph.D. is the Chief Business Development Officer
of Polaryx Therapeutics. Jay has worked at both public/private
institutions as well as at eminent hospitals and Universities
to assess, develop, and commercialize a wide range of
technologies including therapeutics, diagnostics, and medical
devices (from rare diseases to neurodegeneration, cancer,
autoimmunity, and inflammation). He held several senior roles
in technology commercialization in top academic institutions
including as Director of Innovation at the Hospital for
Special Surgery and Head of Technology Commercialization at
Rush University Medical Center. Jay was Co-Founder and
Director of Business Development and Scientific Affairs at
Optimal Vision Corporation. In addition to executive roles, he
has served as scientific advisor to several biotech companies
and most recently as scientific advisor and board member of a
publicly traded company (TLGY: NASDAQ).
Jay received his Ph.D. in Neuroscience from the City
University of New York and completed his postdoctoral training
at the University of Chicago where he conducted research on
trafficking and regulation of key components of the gamma
secretase in Alzheimer’s disease.
Kalipada Pahan, Ph.D. is a Professor of Neurological Sciences,
Biochemistry and Pharmacology and the Floyd A. Davis, M.D.,
Endowed Chair in Neurology at the Rush University Medical
Center in Chicago. Dr. Pahan is also a Veterans Affairs
Scientist at the Jesse Brown VA Medical Center. Currently, he
is engaged in translational biomedical research involving
Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease,
and Batten Disease. He is the Editor-in-Chief of the Journal
of Multiple Sclerosis, Senior Editor of the Journal of
Neuroimmune Pharmacology, Editor of three other journals, and
a chartered member of the Clinical Neuroimmunology and Brain
Tumors study section at the NIH.
Dr. Pahan has over 160 publications. He received the
“Chancellor’s Council Silver U Award” in 2004, and the
"Reinhardt Research Scholar Award” in 2005 from the University
of Nebraska Medical Center. He also received merit awards from
the US Department of Veterans Affairs and the Zenith award
from the Alzheimer’s Association.
Raymond Wang, M.D. is the Director of the Multidisciplinary
Lysosomal Storage Disorder Program at CHOC Children’s Hospital
and a board-certified clinical geneticist and biochemical
genetics specialist. He has participated in clinical trials
for Type 2 Neuronal Ceroid Lipofuscinosis, Pompe Disease,
Niemann-Pick C Disease, and Mucopolysaccharidoses. He also is
the principal investigator for translational research
involving gene therapy and gene editing for treatment of
lysosomal storage disorders.
Dr. Wang graduated from Stanford University with Honors and
Distinction in Biological Sciences. He earned his medical
degree from the University of California, Los Angeles (UCLA),
and completed his internship and residency in medical genetics
and pediatrics at Cedars-Sinai Medical Center where he served
as chief resident in his final year of training. Dr. Wang
completed his fellowship in biochemical genetics at the UCLA
Intercampus Medical Genetics Program. Dr. Wang has been named
an Orange County Clinical Biochemical Genetics Physician of
Excellence in 2015, 2016, 2017, 2018, and 2019 and nominated
for a 2018 Global Genes RARE Champion of Hope Award for his
work with children with rare metabolic conditions.
Angela Schulz, M.D. is the director at Children's Hospital,
NCL Specialty Clinic International Center of Lysosomal Storage
Disorders (ICLD) University Medical Center Hamburg-Eppendorf
Hamburg, Germany. Her areas of expertise include palliative
medicine and neuropediatrics.
Dr. Schulz was the winner of 2005 Wissenschaftspreis der
Gesellschaft für Neuropädiatrie.
Saadet Andrews, M.D., Ph.D. received training in both clinical
metabolic genetics and pediatrics at the Department of
Pediatrics, Vienna General Hospital, University of Vienna,
Austria. Dr. Andrews completed her training on biochemical
genetics fellowship and a one-year fellowship in pediatric
neurology at the University of British Columbia's Division of
Neurology, Department of Pediatrics. She established the first
epilepsy genetics clinic at The Hospital for Sick Children
between 2011 to 2020 and began working as a geneticist at the
University of Alberta's Department of Medical Genetics in
Edmonton. She has also developed the "Epilepsy Genetics
Clinic" in the Department to provide genetic diagnostics to
the children, teenagers and adults with epilepsy in Northern
Alberta.
Dr. Andrews was the winner of the 2015 Epilepsia Clinical
Science Prize for her clinical research study "Diagnostic
yield of genetic testing in epileptic encephalopathy in
Childhood."